Year-end Sale % OFF 
Abstract
Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
Highlights
There are a variet of rowth hormone deliver devices (GHDD) available to children requirin rowth hormone (GH) therap
Research has shown (A ar & Geor e 2016) that involvin the health care professional (HCP) within the decision makin process can have an in uence on the desired GHDD, althou h the HCP referred to was the prescribin Doctor
Nurses had a variet of devices to choose from (N=11): three roups had chosen di erent devices (N=3) apart from two roups had chosen the same device
Summary
There are a variet of rowth hormone deliver devices (GHDD) available to children requirin rowth hormone (GH) therap. Man paediatric endocrine nurses can o er patients and their families a choice of the products that are available, which can sometimes be overwhelmin. Factors such a licensed clinical indications have to be considered, as well as cost. Patient choice for rowth hormone devices is well documented in the literature, with re ards to compliance (Ahmed et al 2008, Gau & Takasawa 2017, Kapoor et al 2008, van Don en & Kaptein 2012, Wickramasuri a et al 2006), with onus on the parents and children makin the nal choice for the deliver of rowth hormone. The proposed model (Elw n et al 2012) is seen below
Sign-in/Register to view highlights & summary 
Submitted Version (
Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
